Planning, requesting medicines and reporting
Integrated preventive chemotherapy implementation
The selection of anthelminthic medicines recommended by WHO for use in public health programmes is designed to control and eliminate helminth infections. Many of these medicines are broad-spectrum, allowing several diseases to be tackled simultaneously. Preventive chemotherapy (PC) interventions should therefore be based on the optimal, coordinated use of available medicines rather than targeting specific forms of helminthiasis. Where operationally feasible and epidemiologically justified, WHO recommends the integrated and coordinated delivery of combinations of anthelminthic medicines to target multiple diseases.
Joint mechanism and tools to support integrated preventive chemotherapy implementation
As part of global efforts to accelerate expansion of preventive chemotherapy for elimination and control of lymphatic filariasis (LF), schistosomiasis (SCH) and soil-transmitted helminthiases (STH), WHO facilitates the supply of the following medicines donated by the pharmaceutical industry: diethylcarbamazine citrate, albendazole, mebendazole, and praziquantel. WHO also collaborates to supply ivermectin for onchocerciasis (ONCHO) and lymphatic filariasis elimination programmes.
A joint mechanism and a set of forms have been developed to facilitate the process of application, review and reporting as well as to improve coordination and integration among different programmes.
- Joint Request for Selected PC Medicines (JRSP) - designed to assist countries in quantifying the number of tablets of the relevant medicines required to reach the planned target population and districts in a coordinated and integrated manner against multiple diseases during the year for which medicines are requested.
- Joint Reporting Form (JRF) - designed to assist countries in reporting annual progress on integrated and coordinated distribution of medicines across diseases in the reporting year in a standardized format.
- Annual work plan – designed to summarize the key activities to be implemented by national programmes, to present timelines and identify gaps in financial and technical resources for implementation. It allows WHO to monitor the progress of the national programmes closely and coordinate provision of support where necessary. A Tool for Integrated Planning and Costing (TIPAC) is available to guide integrated work planning across multiple disease-specific programmes. TIPAC can be utilized to automatically generate the annual work plan.
The three forms must be submitted together. All donations are subject to review and/or availability of medicines. In addition, use of donated medicines must be adequately reported to WHO upon completion of treatment activities. Note that all the forms MUST be submitted to PC_JointForms@who.int no later than 15 August of the year for which medicines are intended to be used (e.g. at the latest by 15 August 2013 for implementation of preventive chemotherapy in 2014).
Form to report epidemiological data
While data on use of PC medicines are reported using the JRF, epidemiological data such as outcomes of monitoring and evaluation or morbidity management activities should be reported using the PC Epidemiological Data Reporting Form (PC EPIRF). This form is designed to standardize national reporting of epidemiological data on lymphatic filariasis, onchocerciasis, soil-transmitted helminthiases and schistosomiasis.
National authorities are encouraged to complete this form and submit it to WHO on a yearly basis, together with the JRF.
Data reporting and collection at community and district levels
Recording and collecting reliable information on the use of medicines (i.e. drug coverage) at peripheral and district levels and compiling such information at the national level is essential for completion of the JRF.